Idelalisib exposure before allogeneic stem cell transplantation in patients with follicular lymphoma: an EBMT survey

L. Sellner, J. Schetelig, L. Koster, G. Choi, D. Blaise, D. Beelen, F.C. Schianca, J. Passweg, U. Schanz, E. Gyan, F. Sora, N. Kroger, G.G. Wulf, G. Van Gorkom, J. Mayer, C. Orvain, J.H. Bourhis, P. Jindra, V. Potter, F. ZallioE. Vandenberghe, S. Robinson, P.J. Hayden, I. Yakoub-Agha, S. Montoto, P. Dreger, S.o.c. European, European Society for Blood and Marrow Transplantation Lymphoma and Chronic Malignancies Working Parties

Research output: Contribution to journalComment/Letter to the editorAcademicpeer-review

Original languageEnglish
Pages (from-to)2335-2338
Number of pages4
JournalBone Marrow Transplantation
Volume55
Issue number12
DOIs
Publication statusPublished - 1 Dec 2020

Keywords

  • inhibition
  • outcomes
  • rituximab
  • trial
  • TRIAL
  • INHIBITION
  • RITUXIMAB
  • OUTCOMES

Cite this